aafp glp 1 SGLT-2 Inhibitors, GLP-1 Agonists Provide Greater Benefit for Patients With Type 2 Diabetes collection_sensolin Quantity:3-Month Delivery Two medications. Both proven.

aafp glp 1 SGLT-2 Inhibitors, GLP-1 Agonists Provide Greater Benefit for Patients With Type 2 Diabetes collection_sensolin Quantity:3-Month Delivery Two medications. Both proven.

Two medications. Both proven. Both physician guided. But they work differently — and the right one depends on your biology, your goals, and where you're starting from. Semaglutide targets one pathway. Tirzepatide

By contrast, Lilly’s orforglipron has no dosing restrictions

collection_sensolin

Quantity:3-Month Delivery

By filing a terminal disclaimer, the applicant discounts the second patent’s term to match the first, and ‘ties’ the two patents together